Companies › Elgan Pharma
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Gastroenterology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ELGN-2112 Human insulin [rDNA] | INS | Phase 3 | Intestinal Malabsorption | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05904626 | ELGN-2112 | Phase 2 | Intestinal Malabsorption | Gastroenterology | Jun 2027 |
| NCT05670951 | ELGN-2112 | Phase 3 | Intestinal Malabsorption | Gastroenterology | Nov 2027 |
Gateway Institute for Brain Research Gan & Lee Pharmaceuticals. Portal Diabetes
Cinclus Pharma Holding Norgine Green Cross Wellbeing Inventiva Pharma Dr. Falk Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.